What’s next for Endpoints — and how to support our independent biopharma news mission
The firehose of biopharma news is gushing these days.
That’s why broader and deeper is the theme for 2021 at Endpoints. You can expect new coverage outside our core R&D focus, with deeper reporting in some key areas. When John Carroll and I launched Endpoints nearly five years ago, we were wading in waist-high waters. Now we’re a team of 25 full-time staffers (and growing) with plans to cover the flood of biopharma news, Endpoints-style.
If you rely on us for news, we’re going to need your help.
The single best way to support us is enrolling in Endpoints Premium, our annual subscription program that unlocks the full Endpoints experience.
We offer two premium plans: Insider for individuals and Enterprise for companies.
- Enterprise — $1,000/year for your entire organization, regardless of size. We offer a rare unlimited-seat license, which makes every employee eligible for Endpoints Premium. In addition to unlocking the paywall for all, employees will receive a custom version of the daily email reports, signifying your company’s support of independent journalism. You can see an example of that in the graphic above. Other benefits include two free premium job listings at Endpoints Careers and a reprints license for sharing our content internally any way you see fit. The application form is here; access is granted instantaneously after payment. We also have a fantastic customer support team to help you get the most from subscribing.
- Insider — $225/year for individuals. With an Insider plan, individual subscribers have the option to disable advertising, in addition to unlocking the content library. If you want just the news content and nothing else, this is the plan for you.
Most importantly, with both plans, you’re directly supporting the future development of Endpoints News. As an independent publication, we’ve avoided raising cash from investors. We report to our paid subscribers and no one else.
To be sure, joining Endpoints Premium is optional. We believe that high-quality reporting ought to be free and easily accessible. So we’re committed to keeping the most essential bits available with our no-cost Basic email subscription.
But as we get broader and deeper in 2021, Endpoints Premium is where you’ll find more of that work. So any company or reader looking for the complete picture should sign up for a paid plan today.
One example of the deeper work you’ll have access to is a printable PDF of all new drug approvals in 2020.
Broader and deeper
We’ve got big plans to cover new ground and it will begin with a new product launch: Endpoints Manufacturing.
Starting in February, every Thursday we’ll deliver the most important stories in manufacturing in one convenient email report. Endpoints reporter Conner Mitchell will be leading our biomanufacturing coverage. It’s a critical beat in the biopharma world and we’re doubling down.
Under the main Endpoints News banner, our growing team has afforded us opportunities to go deeper, too.
Sometimes, it’s in the form of In Focus pieces, like Jason Mast’s exploration into a medical mystery behind a gene therapy trial. It’s also in the Endpoints 11, where John Carroll profiled eleven of biopharma’s most promising startups in September. We went beyond write-ups and delivered lengthy video interviews with the winners at our virtual event, and there’s a treasure trove of knowledge to uncover in these conversations. It’s a must-watch if you’re into biotech entrepreneurship.
That same detail went into Women in Biopharma, our December virtual event. Here you saw contributions from our entire team, led by editors Amber Tong and Nicole DeFeudis. I consider it some of our best work. If you haven’t yet, please take a few minutes to watch the videos of our honorees. It’s a rare treat to hear and learn from these luminaries directly.
We’re going to be doing much more of that in 2021.
For current Endpoints Premium subscribers, thank you — there’s no chance we’d be here today without you. For those of you getting one today, be sure that we have never been more appreciative of your support for the independent mission we have carved out for ourselves as we bootstrapped this startup.